Pete Coffey, Chair, Cellular Therapies and
Visual Sight
Slide one
Regenerative Medicine has the potential to transform medicine
Kidney
 Augment function of falling kidney
 Delay or avoid need for dialysis
 Dramatically improve life expectancy and quality of life
Cardiovascular disease
 Replace damaged cardiac tissue
 Repair function/ejection fraction
 Restore quality and duration of life among survivors of the most
common cause of death
Diabetes
 Replace lost beta cells
 Restore glucose-responsive insulin secretion
 Reduce or eliminate dependence on exogenous insulin
Slide 2 - 15
Images of the pupil and macula
Slide 16
Imagery concerning Age-related Macular Degeneration
Slide 17- 27
Imagery of repopulation, reconstructing the macula, macula
translocation and rotation.
Including stem cell source and potential sourcing of stem cells.
Slide 28
How do you deliver the cells?
The problem of an aged Bruchs membrane
Illustration of: cell suspensions may fail to attach to Bruchs
membrane
Illustration of: solution: manufacture an artificial membrane
Slide 29
How do you deliver the cells?
On an artificial membrane.
Illustration of the cells.
Slide 29 - 41




Illustrations of large patient surgical procedures
RPE Transplantation
Graft installation
What are we repopulating and why?
Slide 42
Proposed trial - phase I/II
Transplantation in acute retinal tear
Transpantation in failing Lucentis Rx
Slide 43
Looking ahead, Regenerative medicine will continue to evolve
- but how?
Restore/replace products with complicated integration
requirements are likely > 15 years away including:
 Organ replacement (eg liver, kidney)
 Replacing infected heart with functioning cells
 Integrated neurological repair (eg. Parkinson's, spinal cord,
ALS)
Mid-term potential (5-15 years):
 Complicated conditions treated with trophic cells (eg. CV,
Stroke)
 Extracorporeal devices (kidney and liver)
 Restore/replace products with fewer integration requirements (
eg. islet replacement, oligodendrocyte restoration, small
molecule/ biologic approaches for endogenous regeneration).
Most likely short term (-5 years) products:
 Trophic therapy?
 Products that restore or augment function that have few hurdles
 (eg. Skin, bone, soft tissue).
Slide 44
The People
Institute of Ophthalmology
 Ahmed Ahmado
 Amanda Carr
 Karen Cheetham
 Li Li Chen
 Carlos Gias
 Amelia Lane
 Jean Laurence
 Ma’ayan Semo
 Matt Smart
 Yasmyn Rybak-Rajewski
 Anthony Vugler
University of Tohoku
 Hiroshi Tomita
Moorfields Eye Hospital
 Lyndon da Cruz
 Fred Chen
 David Stewart
 Jonathan Yeoh
UC Santa Barbara
 Dennis Clegg
 Linc Johnson
 Sherry Hikita
 Jamie Thomson
Pfizer
 Ruth McKernan
 Paul Whiting
 Natalie Mount
 Ron Fedechko
 Steve Hall
 Julie Kerby
 Trevor Mill
 Joann Parker
 Annamaria Rossi
 Michaela Sharpe
 Bruce Williams